



Appellate Ruling Affirms Decision in Favor of Sun Pharma Global FZE

November 20, 2014

Upholding a United States District Court for the District of Delaware decision in favor of Katten client Sun Pharma Global FZE and several other generic-drug makers, the Federal Circuit Court recently declared invalid two patents for Warner Chilcott Co. LLC's osteoporosis drug Actonel. The appellate panel agreed that the Actonel patents were invalid, citing prior art disclosures of the patents' limitations for oral administration, once-monthly frequency and dosage. The panel further denied the plaintiffs' motion for an injunction pending appeal. Intellectual Property partners Eric Cohen and Stephen Benson represented Sun Pharma in this matter in the Delaware court. ("[Fed. Circ. Affirms Warner Chilcott's Actonel Patents Invalid](#)," November 18, 2014)

Attorney advertising. Published as a source of information only. The material contained herein is not to be construed as legal advice or opinion.

©2025 Katten Muchin Rosenman LLP.

All rights reserved. Katten refers to Katten Muchin Rosenman LLP and the affiliated partnership as explained at katten.com/disclaimer.